Maraciclatide enables non-invasive detection of endometriosis in clinical trial

8 articles · Updated · The Guardian · Apr 29

A University of Oxford-led trial using maraciclatide involved 19 women, with scans correctly identifying endometriosis in 16 cases and producing no false positives.
This radiotracer, developed by UK-based Serac, could replace invasive surgery for diagnosis, particularly for superficial peritoneal endometriosis, and is set for larger phase 3 trials.
Endometriosis affects about one in ten women, with diagnosis in England averaging over nine years; a reliable, minimally invasive scan could transform research, treatment, and patient outcomes globally.

Will this advanced scan widen the healthcare gap for endometriosis patients globally?

Is a high-tech scan the real solution, or must we first fix doctors dismissing women's pain?

Could a simple blood test soon make even this advanced imaging technology obsolete?

With radiation involved, what are the long-term safety concerns for repeated scans in young women?

With FDA Fast Track, how quickly could this scan become a clinical reality for millions?

Beyond diagnosis, can this new scan measure disease severity or track treatment effectiveness?